Design Therapeutics Q4 net loss $17.3M; FY2022 net loss $63.3M; cash $330M; DT-216 MAD data mid-2023

Design Therapeutics, Inc.

R&D expenses $14.3M (Q4) and $48.6M (FY2022); G&A $5.1M (Q4) and $19.0M (FY2022).
Cash, equivalents and securities $330.4M as of Dec 31, 2022; expected runway through 2025.
Phase 1 MAD trial of DT-216 for Friedreich Ataxia ongoing; initial data expected mid-2023, final by year-end.
IND submission for DT-168 (FECD) planned H2 2023; DM1 program targeting IND in 2024.
No revenue reported; net loss driven by R&D investment in clinical and preclinical pipeline.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Design Therapeutics, Inc. reported three and twelve months ended December 31, 2022 results: net income Net loss was $17.3 million for the quarter ended December 31, 2022, and $63.3 million for the year ended December 31, 20.

Period: three and twelve months ended December 31, 2022
Net income: Net loss was $17.3 million for the quarter ended December 31, 2022, and $63.3 million for the year ended December 31, 20
Result: reported results

Exact text from the filing

On March 14, 2023, Design Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Design Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-007864

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.